Oncolytic reovirus can be delivered both systemically and intratumorally, in both preclinical
models and in early phase clinical trials. Reovirus has direct oncolytic activity against a …

Vesicular stomatitis virus (VSV) suppresses antiviral responses in infected cells by inhibiting
host gene expression at multiple levels, including transcription, nuclear cytoplasmic …

The anti-tumour effects associated with oncolytic virus therapy are mediated significantly
through immune-mediated mechanisms, which depend both on the type of virus and the route …

Background Systemic delivery of a complementary cDNA library expressed from the
vesicular stomatitis virus (VSV) treats tumors by vaccinating against a wide range of tumor …

These findings imply that molecularly heterogeneous GBM lines share selective senescence-induced
BCL-XL dependency increase the significance and translational relevance of the …

High-grade gliomas are primary brain tumors that are incredibly refractory long-term to
surgery and chemoradiation, with no proven durable salvage therapies for patients that have …

Glioblastoma is the most common adult primary brain tumor and carries a dismal prognosis.
Radiation is a standard first-line therapy, typically deployed following maximal safe surgical …

Systemic viroimmunotherapy activates endogenous innate and adaptive immune responses
against both viral and tumor antigens. We have shown that therapy with vesicular stomatitis …

Oncolytic viruses (OV) preferentially kill cancer cells due in part to defects in their antiviral
responses upon exposure to type I interferons (IFNs). However, IFN responsiveness of some …

Oncolytic viruses represent a diverse class of replication competent viruses that curtail tumor
growth. These viruses, through their natural ability or through genetic modifications, can …